Nanoxel-M Inj（多西他赛无水冻干粉注射剂）
商标名称：Nanoxel M Inj
通用名称：多西他赛
治疗类别：生物碱
描述
多西他赛无水静脉制剂，Nanoxel-M™采用基于聚合物的递送系统的开发，本品包含在无色透明的小瓶为白色或淡黄色粉末或多孔光硬块的冻干注射毒品。
使用融化。
成分
一小瓶Nanoxel中号注射液（500毫克）
多西紫杉醇无水..................................... 20毫克
一小瓶Nanoxel中号注射液（2000毫克）
多西紫杉醇无水..................................... 80毫克
用法，用量
75-100毫克/米2，应静脉内注射为每三周一小时
生产商：韩国 Samyang Biopharm
Nanoxel® M Inj
Product: Nanoxel M
Generic Name: docetaxel
Therapeutic Subcategory: Alkaloids
Effcacy,Effecf
Breast cancer
Along with doxorubicin, Nanoxel is administered as a primary drug for locally progressed or metastatic breast cancer.
Along with trastuzumab, the drug is administered for metastatic breast cancer with the excessive manifestation of HER2
(human epidermal growth factor receptor 2 protein) and with no chemotherapy experience.
Locally progressed or metastatic breast cancer that the previous chemotherapy failed to arrest
Along with capecitabine, the drug is administered for locally progressed or metastatic breast cancer
that the administration of anthracycline drugs and that chemotherapy failed to arrest.
Along with doxorubicin and cyclophosphamide, the drug is administered as an adjuvant therapy after operation
for operable-lymph-node-positive breast cancer.
Non-small-cell lung cancer
Locally progressed or metastatic non-small-cell lung cancer, including cases that
the platinum chemotherapies failed to arrest
Prostate cancer
Along with prednisolone, the drug is administered for the treatment of androgen non-dependent (hormone-unresponsive)
metastatic prostate cancer.
Ovarian cancer
Along with carboplatin, the drug is administered as a primary drug for progressed
or metastatic epithelial ovarian cancer.
Head and neck cancer
Along with cisplatin and 5-fluorouracil is administered as an induction therapy for locally progressed
squamous-cell carcinoma in the head and neck.
Gastric cancer
Administered alone for progressive and metastatic or locally recurrent gastric cancer.
Together with cisplatin and 5-fluorouracil, the drug is administered as a primary drug for metastatic or locally recurrent gastric cancer.
Esophageal cancer
Progressive or recurrent esophageal squamous-cell carcinoma.
Description
A freeze-dried injection drug contained in a colorless and transparent vial as white or pale-yellow powder or porous light lumps.
Use melted.
lngredients
One-vial Nanoxel M Injection (500mg)
Docetaxel anhydrous..................................... 20mg
One-vial Nanoxel M Injection (2000mg)
Docetaxel anhydrous..................................... 80mg
usage,Dosage
75-100 mg/m2 should be intravenously injected for one hour every three weeks.
To minimize the serious hypersensitivity reaction and fluid retention that may be manifested during the administration of this drug, pretreatment should be performed. For the pretreatment, if not banned, for three days leading to one day before administering this drug, oral corticosteroid should be administered (for dexamethason, 16 mg each day — e.g., twice, with 8mg administered each time — should be administered). Thus, to ease the danger of haematological toxicity, G-CSF can be proactively administered.
In hormone-unresponsive, metastatic prostate cancer, if administered together with prednisone, it is recommended that as a pretreatment, 8mg oral dexamethasone be administered 12 hours, 3 hours, and 1 hour before the administration of this drug.
